A preparation of autologous human T-lymphocytes isolated from renal cell cancer (RCC) patient and transduced with 2G-1 TCR, a retroviral vector encoding the alpha and beta chains of a T-cell receptor that recognizes TNF-related apoptosis inducing ligand (TRAIL) bound to death receptor 4 (DR4), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and introduction into the RCC patient, 2G-1 TCR retroviral vector-transduced lymphocytes may stimulate a cytotoxic T lymphocyte (CTL) response against RCC cells with TRAIL bound to DR4 on their surfaces. TRAIL, a member of the TNF superfamily, is a homotrimeric type II membrane protein that rapidly induces oligomerization of receptor intracellular death domains and apoptosis in a variety of tumor cells when bound to its receptors; DR4 (TRAIL receptor 1), a member of the TNF receptor family, is overexpressed by a variety of malignant cell types.
class Information
C82408
_2G-1_TCR_Retroviral_Vector-Transduced_Lymphocytes
639521
CL408672
639521
639521
2G-1 TCR Retroviral Vector-Transduced Lymphocytes
- Cell
- Pharmacologic Substance
class Relations
- Antineoplastic Immune Cell
- T-cell Receptor-engineered T-cells
- Therapeutic Autologous Lymphocytes
- Chemical_Or_Drug_Has_Mechanism_Of_ActionsomeAntigen Sensitization
- Chemical_Or_Drug_Has_Physiologic_EffectsomeT-Cell Activation
- Chemical_Or_Drug_Has_Physiologic_EffectsomeImmunopotentiation
- Chemical_Or_Drug_Affects_Cell_Type_Or_TissuesomeCytotoxic T-Lymphocyte